Choosing the best treatment for severe aortic valve disease has become increasingly important as more people live longer and more younger patients become eligible for valve replacement.
A new study published in JAMA Cardiology provides reassuring news.
Researchers found that a minimally invasive valve replacement procedure performed just as well as traditional open-heart surgery over seven years for patients considered at low surgical risk.
Heart valves work like small doors inside the heart. They open to let blood move forward and close to stop blood flowing backward. When a valve becomes damaged, the heart cannot pump efficiently.
Aortic stenosis, one of the most common valve diseases, happens when the aortic valve becomes narrow and stiff. This forces the heart to pump harder and can eventually cause chest pain, fainting, heart failure and death if left untreated.
For many years, open-heart surgery was the standard treatment. More recently, doctors developed TAVR, which allows a new valve to be placed through a catheter without opening the chest. Recovery is usually faster, but doctors have wanted stronger evidence that these valves remain reliable over many years.
The PARTNER 3 clinical trial randomly assigned 1,000 low-risk patients to receive either TAVR with the SAPIEN 3 valve or standard surgical valve replacement. Patients underwent regular echocardiograms for seven years so researchers could measure valve function, durability and complications.
The findings showed remarkably similar results. Serious valve deterioration affected 7.3% of TAVR patients and 7.6% of surgical patients.
Valve failure rates were also nearly identical, while only a small proportion of patients in either group required another valve replacement. About 75% of participants were alive with a working replacement valve after seven years.
One finding stood out. Blood clots on the replacement valve occurred more often after TAVR than after surgery, affecting 5.2% compared with 0.9% of patients. This suggests doctors should continue monitoring patients after TAVR so problems can be treated before they become serious.
These results provide strong evidence that TAVR is no longer only an option for patients who cannot tolerate surgery. It can also deliver excellent long-term outcomes for many lower-risk patients.
Even so, treatment decisions should still be tailored to each individual, taking into account age, overall health, personal preferences and future medical needs. Since many younger patients may live for decades after valve replacement, studies with even longer follow-up will remain important.
Overall, this research represents an important milestone because it shows that minimally invasive heart valve replacement can match surgery in durability while identifying an area where continued monitoring can further improve patient care.
If you care about heart health, please read studies about the best time to take vitamins to prevent heart disease, and calcium supplements could harm your heart health.
For more health information, please see recent studies that blackcurrants can reduce blood sugar after meal and results showing how drinking milk affects risks of heart disease and cancer.
Source: PARTNER 3 investigators.
